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Abstract
Background
Deep brain stimulation (DBS) has been proposed as an alternative to ablative neurosurgery
for severe treatment-resistant Obsessive-Compulsive Disorder (OCD), although with par-
tially discrepant results probably related to differences in anatomical targetting and stimula-
tion conditions. We sought to determine the efficacy and tolerability of DBS in OCD and the
existence of clinical predictors of response using meta-analysis.
Methods
We searched the literature on DBS for OCD from 1999 through January 2014 using
PubMed/MEDLINE and PsycINFO. We performed fixed and random-effect meta-analysis
with score changes (pre-post DBS) on the Yale-Brown Obsessive Compulsive Scale
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(Y-BOCS) as the primary-outcome measure, and the number of responders to treatment,
quality of life and acceptability as secondary measures.
Findings
Thirty-one studies involving 116 subjects were identified. Eighty-three subjects were
implanted in striatal areas—anterior limb of the internal capsule, ventral capsule and ventral
striatum, nucleus accumbens and ventral caudate—27 in the subthalamic nucleus and six
in the inferior thalamic peduncle. Global percentage of Y-BOCS reduction was estimated at
45.1% and global percentage of responders at 60.0%. Better response was associated with
older age at OCD onset and presence of sexual/religious obsessions and compulsions. No
significant differences were detected in efficacy between targets. Five patients dropped out,
but adverse effects were generally reported as mild, transient and reversible.
Conclusions
Our analysis confirms that DBS constitutes a valid alternative to lesional surgery for severe,
therapy-refractory OCD patients. Well-controlled, randomized studies with larger samples
are needed to establish the optimal targeting and stimulation conditions and to extend the
analysis of clinical predictors of outcome.
Introduction
Obsessive-compulsive disorder (OCD) is characterized by the presence of upsetting, persistent
thoughts, images, or impulses, which are experienced as intrusive and senseless (obsessions)
and/or excessive repetitive behaviors or mental acts (compulsions) intended to neutralize the
anxiety induced by the obsessions [1]. OCD has a lifetime prevalence of 2.3% [2] and causes
substantial dysfunction in social adjustment, employment, marriage, family relationships and
socioeconomic status [3]. Despite exhaustive use of optimal behavioral and pharmacological
treatments, an estimated 10% of OCD patients remain resistant to all therapies and suffer from
severe symptoms leading to marked functional impairment [4]. Deep brain stimulation (DBS)
has been proposed as a last-resort option and an alternative to stereotactic lesional neurosur-
gery for this group of extremely disabled patients. DBS permits focal, adjustable and reversible
neuromodulation through the implantation of electrodes that send electrical impulses to spe-
cific locations in the brain. In recent years DBS has been tested as a therapeutic option for sev-
eral neuropsychiatric conditions including OCD, depression, anorexia nervosa and addictions
[5]. In the case of OCD, the therapeutic effect of DBS has been tentatively related to its capacity
to modulate abnormal activity and synaptic connectivity in circuits involving the orbitofrontal
cortex (OFC), anterior cingulate cortex (ACC) and striatum [6], brain areas that have been
implicated in the pathophysiology of the disorder [7]. Reductions in OCD severity in response
to DBS range from 52–54% in patients receiving ventral capsule/ventral striatum (VC/VS) or
nucleus accumbens (NA) stimulation to 41% in those with electrodes implanted in the subtha-
lamic nucleus (STN) [8]. Percentage of responders–subjects with a reduction in their symptom
severity of at least 35%–varies from 10% [9] to 61.5% [10]. These discrepant results may be at
least partially related to the differences in anatomical targeting, electrode design and stimula-
tion protocols used. Certain data also suggest that some manifestations of the disorder, i.e.
“just-right” experiences or the need for symmetry, may be less likely to respond to DBS [11,
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12], although the low number of patients included in each study has complicated the identifica-
tion of clinical markers of response. In view of the clinical heterogeneity of the disorder, the
analysis of these predictors would be extremely helpful to facilitate the selection of candidates
for DBS since the technique is not free from potentially severe adverse effects and is a highly
economical and human resources requesting option.
So, the goal of the current meta-analysis was 1) to systematically record the treatment effects
of DBS in severe therapy-refractory OCD patients, and 2) to identify any clinical variables asso-
ciated with a better response to this therapeutic approach.
Material and Methods
Search strategy for identification of studies
We performed a comprehensive PubMed/MEDLINE and PsycINFO search from January 1999
through January 30, 2014, including the following terms: “deep brain stimulation” or “DBS” in
association with “obsessive-compulsive”, “obsessive-compulsive disorder” or “OCD”. These
words were searched as key words, title, abstract and Medical Subject Headings. Reference lists
from retrieved reports were reviewed for additional relevant studies.
Selection of studies
Candidate studies–judged on the basis of their title and abstract–had to satisfy the following
criteria to be eligible for inclusion in this review: 1) human studies assessing the efficacy of DBS
on OCD according to changes on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
scores or percentage of responders defined by standardized criteria; 2) subjects aged 18–75
years with a diagnosis of OCD according to the Diagnostic and Statistical Manual of Mental
Disorders IV [1] or International Classification of Diseases criteria [13]; 3) studies published in
English in peer-reviewed journals.
Exclusion criteria:
- reviews of DBS use for OCD not providing results from de novo patients
- discussions of ethical issues related to DBS
- articles focused on biological correlates of DBS use in OCD–neuroimaging, electrophysiologi-
cal or neuropsychological changes after DBS
- articles focused on the secondary side effects of chronic DBS use in OCD or effects observed
during acute stimulation programming
- articles focused on other indications of DBS different from OCD
- articles focused on neurosurgical issues related to DBS implantation for OCD
- studies on animal models of DBS use in OCD
Data extraction
Data were recorded as follows:
- sample characteristics: age, gender, age at onset of OCD, duration of OCD, OCD symptom
dimensions.
- DBS-related: brain target, lead model, duration of stimulation.
- study-related: single or double-blind; sham-controlled; parallel or crossover designs
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- primary outcome measure: score changes (pre-post DBS) on the Y-BOCS
- secondary outcome measure: number of responders to treatment based on standardized crite-
ria (> 35% reduction in post-treatment Y-BOCS scores) and changes on quality of life
(QOL) measures
- acceptability of treatment: overall dropout rates and side effects
Data synthesis and analyses
Analyses were performed using the statistical software R3.0.1 [14] with meta package for meta-
analysis [15] and IBM SPSS Version 20 (IBM Corporation, Chicago, IL, USA). Weighted pro-
portion meta-analysis was used to adjust for study size using the DerSimonian-Laird model
to allow for heterogeneity inclusion in the analysis. Effect sizes were calculated with fixed and
random-effects models, and risk ratios were presented as a forest plot. The forest plot shows
study-specific risk ratios (and their 95% CIs) and the relative weighted contribution of each
study, as well as the risk ratio estimate pooled across all studies. Heterogeneity was assessed
using the Q statistics and I2 index [16]. Values of p< 0.1 for the former and> 35% for the latter
were deemed as indicative of between-study heterogeneity [17]. Student’s “t” test and Spear-
man’s rank correlation were used to analyze the association of age and age at OCD onset with
response to DBS. Pearson’s chi squared test and Wilcoxon test were used to study gender dif-
ferences and influence of neuroanatomical target on response to DBS. Finally, Fisher’s exact
test was used to assess differences on response to DBS according to OCD symptom
dimensions.
Results
Literature search
Flow of information according to PRISMA statement, study selection and reasons for exclusion
are provided in Fig 1. Our electronic and reference list search found 301 studies, after discard-
ing duplicates, that were potentially relevant to this meta-analysis. Of these, 270 were not
included in the analysis because they met exclusion criteria. Thirty-three articles met the eligi-
bility criteria (see Table 1). One was excluded because it was the abstract of a poster presenta-
tion [18] and another reported results on comorbid Anorexia Nervosa in an OCD patient
treated with DBS but did not provide information on changes in OCD symptoms [19].
Studies included: main characteristics
Thirty-one studies were included in this meta-analysis [9–12, 20–46], comprising 116 subjects
with OCD treated with DBS (S1 Table). The main characteristics of the studies included are
described in Table 1. Twenty-four studies including 83 patients addressed DBS of “striatal
areas”, including the anterior limb of the internal capsule (ALIC), the ventral capsule and ven-
tral striatum (VC/VS), the nucleus accumbens (NA) or the ventral caudate nucleus; five studies
including 27 patients reported results on stimulation of the subthalamic nucleus, and two stud-
ies fromMexico, including six patients, described results of DBS applied at the inferior tha-
lamic peduncle. Stimulation parameters were highly heterogeneous between studies: although
all them employed high frequency stimulation (from 100 to 130 Hz), pulse width ranged from
60 to 450 μs and voltage from 2 to 10,5 V; different models of electrodes (3387, 3887, 3487;
Medtronic Inc, Minneapolis, Minnesota) as well as active contact points were also used in the
different samples. Authors of some of the articles included in the meta-analysis were contacted
to gather further information.
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Pre-post severity of OCD symptoms
Patient-level data relating to Y-BOCS score changes were available for 13 studies, including 66
patients. Mean percentages of reduction, standard deviation and standard error for each study
were calculated to perform the meta-analysis on the percentage of improvement. The fixed
effect model could not be used since it overestimates the percentage of improvement due to the
excessive weight of Mallet et al.’s results [21] in two patients with high and almost identical
percentages of improvement. The random effect model estimates the global percentage of
improvement at 45.1% (95% CI = 29.4% to 60.8%). This wide confidence interval can be attrib-
uted to the reduced sample size of the studies as well as to their heterogeneity (Q = 734.6,
df = 12, p<0.0001; I2 = 96.4%) (see Fig 2 for the associated Forest Plot)
Percentage of responders
Response to treatment–defined by operationalized criteria as a reduction on Y-BOCS
scores> 35%–was analyzed in studies including more than one subject in order to estimate its
variability. Patient-level data was available from 12 studies, while four provided results on
pooled data (percentage of responders in the study). A fixed effect model estimated the global
percentage of responders at 60.0% (95% CI = 49.0% to 69.0%). The random effect model
detected identical results due to the low sample size of the studies. Results for Q statistics
Fig 1. Flow of information according to PRISMA statement, study selection and reasons for exclusion.
doi:10.1371/journal.pone.0133591.g001
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Table 1. Characteristics of the 31 studies included in the meta-analysis.
Authors Year Number of
patients
Number of
new patients
Final observation
period (months)
DBS target Double
blind
% Y-BOCS
reduction
Responders
(ratio)
Nuttin et al. [20] 1999 1* 1 Unknown ALIC Yes Unknown 1/1
Mallet et al. [21] 2002 2 2 6 Subthalamic
nucleus
No 80.7–82.6% 2/2
Gabriels et al.
[22]
2003 3 2a 15–31 ALIC 2 Yes/1
No
21–50% 1 /2
Nuttin et al. [23] 2003 8 5b 21–31 ALIC 2 Yes/3
No
17.6–57.8% 2 /3 l
Anderson &
Ahmed [24]
2003 1 1 3 ALIC No 79.4% 1/1
Sturm et al. [25] 2003 4 4 24–30 Nucleus
accumbens
No Unknown 3 /4
Fontaine et al.
[26]
2004 1 1 12 Subthalamic
nucleus
No 96.8% 1/1
Aouizerate et al.
[27]
2004 1 1 27 Ventral caudate
nucleus
No 52.0% 1/1
Aouizerate et al.
[28]
2005 1 0 27 Ventral caudate
nucleus
No
Abelson et al.
[29]
2005 4 4 4–23 ALIC Yes 0–73.3% 2/4
Greenberg et al.
[12]
2006 10 10 6–36 ALIC No 35.5% j 4/8 m,n
Kuhn et al. [30] 2007 1 1 30 Nucleus
accumbens
No 52% 1/1
Plewnia [31] 2008 1 1 12 ALIC No Unknown 1/1
Guehl et al. [32] 2008 3 2d 12 Ventral caudate
nucleus
No 52–71.4% 2/2
Mallet et al. [33] 2008 16 16 3 Subthalamic
nucleus
Yes 37.8% 7/16
Aouizerate et al.
[34]
2009 2 0 30 Ventral caudate
nucleus
No
Jiménez-Ponce
et al. [35]
2009 5 5 12–36 Inferior thalamic
peduncle
No 40–58.3% 5/5
Servello et al.
[36]
2009 4 4 9–19 ALIC No 9.0–60.5% 2/4
Huff et al. [9] 2010 10 10 12 Nucleus
accumbens
Yes 0–55.5% 1/10
Greenberg et al.
[10]
2010 26 8f 3–36 VC/VS Yes 0–62.1% 3/5 o
Goodman et al.
[37]
2010 6 1g 12 VC/VS Yes 91.3% 1/1
Burdick et al.
[38]
2010 1 0h 30 ALIC Yes
Denys et al. [11] 2010 16 16 21 Nucleus
accumbens
Yes 46% j 9/16 m
Franzini et al.
[39]
2010 2 2 24–27 Nucleus
accumbens
No 33.3–44.7% 1 /2
Piallat et al. [40] 2011 9 6i Unknown Subthalamic
nucleus
Unknown Unknown Unknown
Tsai et al. [41] 2012 4 4 15–21 VC/VS No 0–70.5% 2/4
Chabardes et al.
[42]
2012 4 4 6 Subthalamic
nucleus
No 34.3–72.4% 1 /2
(Continued)
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(Q = 13.47, df = 15, p = 0.63) and I2 index (I2 = 0%) suggested that the low sample sizes did not
permit a correct estimation of heterogeneity (see Fig 3 for the associated Forest Plot).
Quality of life
Information on the impact of DBS on quality of life was available for 29 patients [9, 37, 47].
Goodman et al., [37] described a significant increase of the Medical Outcomes Study Short
Form Health Survey (SF-36) vitality score after one year of chronic stimulation of the anterior
limb of the internal capsule and adjacent ventral striatum. Similarly, Huff et al., [9] reported a
significant improvement of quality of life assessed through the Modular System of Quality of
Life (MSLQ) (from 41.3 ± 15.8 to 53.2 ± 19.8) in a group of 9 patients stimulated at VC/VS for
twelve months. Finally, Ooms et al., [47] detected a significant improvement of 90% over time
in the general WHO Quality of Life Scale-Brief Version score (WHOQOL-BREF) as well as in
the physical (39.5%), psychological (39.5%) and environmental (16%) domains of the scale in
13 of the 16 patients included in Denys et al’s study who underwent DBS of the nucleus accum-
bens for 3 to 5 years.
Table 1. (Continued)
Authors Year Number of
patients
Number of
new patients
Final observation
period (months)
DBS target Double
blind
% Y-BOCS
reduction
Responders
(ratio)
Jimenez-Ponce
et al. [43]
2012 6 1k 36 Inferior thalamic
peduncle
No 82.5% 1/1
Roh et al. [44] 2012 4 4 24 VC/VS 45.7–61.1% 4/4
Grant et al. [45] 2012 1 1 8 Nucleus
accumbens
No 68.7% 1/1
Sachdev et al.
[46]
2012 1 1 8 Nucleus
accumbens
No 90% 1/1
Total 116
ALIC: Anterior limb of the internal capsule
VC/VS: Anterior limb of the internal capsule–ventral capsule- and ventral striatum
Response deﬁned as a reduction of Y-BOCS scores > 35%
* The authors make reference to four patients with severe OCD treated with DBS but information is provided just for one.
a One patients included in Nuttin et al., 1999 [20]
b Three patients included in Gabriels et al., 2003 [22]
c Patient included in Aouizerate et al., 2004 [27]
d One patient included in Aouizerate et al., 2004 [27]
e Patients included in Guehl et al., 2008 [32]
f Ten patients included in Greenberg et al., 2006 [12] and ﬁve patients included in Nuttin et al., 2003 [23]
g Five patients included in Greenberg et al., 2010 [10]
h Patient included in Goodman et al., 2010 [37]
i Three patients included in Mallet et al., 2008 [33]
j Two patients included in Mallet et al., 2008 [33]
k Five patients included in Jimenez-Ponce et al., 2009 [35]
l Information on long term response available for 3 patients
m Individual data not available, results correspond to mean results from the study
n Information available in 8 patients
o Information available in 5 patients
doi:10.1371/journal.pone.0133591.t001
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Clinical predictors of response
DBS targets. Patient-level data were available for 45 patients who received DBS in striatal
areas–including VC/VS, ALIC, NAc and NC–and 21 patients who were implanted in the STN.
No significant differences were detected between the two targets in terms of the percentage of
reduction in Y-BOCS scores (striatal: 39.0% ± 25.2 versus STN: 46.3% ± 31.5, t: -1.0, df = 64, p-
value = 0.3) or in percentage of responders (striatal: 55.5% versus STN: 52.3%, χ2 = 0.06,
p = 0.8).
Age and gender. No significant differences were detected between responders and non-
responders to DBS in terms of age (responders 38.6 years ± 11.1 versus non-responders 37.2
years ± 8.4, t: -0.6, df = 74.9, p-value = 0.5) or gender (responders: 26/19 male/female; non-
responders: 20/14 male/female, χ2 = 0.009, p = 0.9). Current age was not correlated with per-
centage of Y-BOCS score reduction (Spearman’s Rho = 0.07, p = 0.5). No significant differ-
ences were detected between males and females in percentage of Y-BOCS score reduction
(male: 41.7% ± 27.1 versus female: 43.4% ± 27.0, Wilcoxon test W = 272.5, p = 0.2) (S2 Table).
Age at OCD onset. Responders to DBS reported a significantly older age at onset of OCD
than non-responding patients (responders 17.1 years ± 7.9 vs non-responders 13.7 years ± 6.9,
t = -2.0, df = 67.1, p = 0.04, 95% CI = -6.7 to -0.03). A tendency was detected for a significant
positive correlation between age at onset of OCD and percentage of Y-BOCS scores reduction
after DBS (Spearman’s Rho = 0.2, p = 0.05).
No significant differences in years of OCD duration prior to DBS implantation were
detected between responders and non-responders (responders 20.5 years ± 11.1 vs non-
responders 23.8 years ± 9.1, t = 1.3, df = 68.9, p = 0.1).
OCD symptom dimensions. No significant differences between responders and non-
responders to DBS were detected for the presence of aggressive/checking symptoms (respond-
ers: 42.5% vs non-responders: 31.2%, Fisher’s Exact test OR = 3.2, p = 0.1, 95% CI = 0.5 to
Fig 2. Forest Plot for percentage of improvement in Y-BOCS scores.
doi:10.1371/journal.pone.0133591.g002
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34.8), contamination/cleaning (responders: 45.1% vs non-responders: 59.3%, Fisher’s Exact
test OR = 1.4, p = 0.7, 95% CI = 0.3 to 6.9), symmetry/ordering (responders: 30.1% vs non-
responders: 34.3%, Fisher’s Exact test OR = 0.5, p = 0.5, 95% CI = 0.1 to 2.4), hoarding
(responders: 7.5% vs non-responders: 3.1%, Fisher’s Exact test OR = 1.3, p = 1, 95% CI = 0.09
to 78.6), and somatic obsessions and compulsions (responders: 15.6% vs non-responders:
7.1%, Fisher’s Exact test OR = 3.2, p = 0.1, 95% CI = 0.5 to 34.8).
Responders more frequently reported obsessions and compulsions of sexual/religious con-
tent than non-responders (responders: 33.0% vs non-responders: 0%, p = 0.009) (S2 Table).
Acceptability of treatment
Five patients dropped out from DBS without completing the planned period of stimulation,
representing 4.7% of the implanted patients. Two of these cases were in the early study by Nut-
tin et al. [23]; both patients finally underwent anterior capsulotomy due to the limited benefits
of DBS and extremely fast battery depletion. The other three subjects were from the Mexican
group who received DBS at the inferior thalamic peduncle [35]. One died of a cocaine over-
dose, another presented tuberculous meningitis and was explanted, and the last one stopped
attending follow-up controls after 18 months of DBS. Side effects reported in the various stud-
ies are presented in Table 2.
Fig 3. Forest Plot for percentage of responders according to standardized criteria (> 35% reduction in post-treatment Y-BOCS scores).
doi:10.1371/journal.pone.0133591.g003
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Discussion
The aim of this study was to measure the response to DBS in severe treatment-resistant OCD
patients using meta-analysis. The data available from 116 subjects produced a global percent-
age of Y-BOCS score reduction of 45.1% and a global percentage of responders of 60.0%. Better
response to DBS was associated with older age at OCD onset and with the presence of sexual/
religious obsessions and compulsions. No significant differences were detected in the percent-
age of responders or in Y-BOCS score reduction between patients who received stimulation of
striatal areas and those with STN implanted electrodes.
These results confirm that DBS appears to have an efficacy comparable to that reported for
capsulotomy or cingulotomy, ablative techniques after which 64% and 56% of patients respec-
tively are rated as significantly improved [48, 49]. Nevertheless, severe adverse effects seem to
Table 2. Adverse effects of DBS reported in the studies included in the meta-analysis.
ADVERSE EVENT n %
Surgery related
Intracerebral hemorrhage 3 2.6
Wound infection 5 4.3
Headache 7 6.0
Tonico-clonic seizure 1 0.9
Scalp tingling or numbness 7 6.0
Device related
Feeling of extension leads, mainly in neck and ear area 10 8.6
Feeling of neurostimulator in chest or abdomen 2 1.7
Break in a stimulating lead or an extension wire 3 2.6
Stimulation related
Hypomanic symptoms 23 19.8
Disinhibition* 7 6.0
Transient confussion 1 0.9
Stomachache, dizziness, nausea 7 6.0
Enuresis 3 2.6
Olfactory perceptions 4 3.4
Paresthesias, tingling 4 3.4
Tightness at jaw area 2 1.7
Diplopia 1 0.9
Weight gain 5 4.3
Weight loss 1 0.9
Insomnia 4 3.4
Forgetfulness, difﬁculty ﬁndings words, memory complains 9 7.8
Anxiety worsening 25 21.6
Panic attacks 1 0.9
Throbbing, ﬂushing** 12 10.4
Depressive mood 5 4.3
Suicidal ideation 4 3.4
Impulsivity 2 1.7
Speech disturbances 2 1.7
*Not fullﬁlling criteria for hypomanic episode
** Without other symptoms of a panick attack
doi:10.1371/journal.pone.0133591.t002
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be less frequent with DBS than with lesional neurosurgery. Three cases of intracranial hemor-
rhages were reported, representing 2.6% of the total number of patients, compared with figures
of 15.8% in some studies of ablative interventions [50]. Five subjects presented an infection of
the scalp, chest or abdominal wound, but they were controlled with antibiotic therapy, and just
one patient suffered a tonic-clonic seizure. Interestingly, no persistent frontal syndrome, cogni-
tive impairment or personality changes have been described for OCD patients receiving DBS.
The most frequent stimulation-related adverse effect was a hypomanic state or at least some
kind of mood disinhibition, reported in nearly one from five patients. Transient worsening of
anxiety while searching for optimal stimulation parameters has also been frequently described.
Nevertheless, almost all studies describe these stimulation-related adverse effects as mild, tran-
sient and reversible after the adjustment of the stimulation parameters. Five drop-outs were
registered among the 116 implanted patients worldwide. Two of them were patients in the
early study in Belgium by Nuttin et al. [23], when experience in the use of the technique was
still limited, while the last three were from the Mexican group implanted at the inferior tha-
lamic peduncle [35]. This Mexican sample is not obviously comparable to others included in
this meta-analysis, since 50% of the subjects presented alcohol and cocaine dependence, a
comorbidity generally considered as an exclusion criterion for DBS use in OCD. So DBS,
although not an innocuous procedure, appears to constitute a safe therapeutic option for severe
treatment-resistant OCD patients, associated with mild and transient emotional and somatic
side effects. On the other hand, DBS imposes its own burdens including need for programming
by an expert center, battery depletion, device failures, need for urgent interventions in the
event of an emergent DBS-related side effect and high economic cost.
Most published studies focus their attention on symptom reduction after DBS and scarce
data is available for changes on quality of life in these highly-resistant and chronic severally ill
patients [9, 37, 47]. Although results are not easily comparable because of the heterogeneity of
the assessment tools, studies suggest that despite the invasive nature of the treatment and the
discomfort derived from the surgical procedure and the stimulation process, most patients
report a significant improvement in at least some aspects of their quality of life. Interestingly,
this improvement was not directly correlated with the reduction of symptom severity and was
reported even by non-responding patients. Moreover QOL keep on improving years after DBS
initiation, even when no further reduction of OCD severity was evident, suggesting than factors
other than OCD intensity–anxiety release, reward processing and motivation, affective status-
influence QOL and that patients need time to adapt to and benefit of their new situation.
Distant DBS effects on abnormal neural connectivity in the cortico-striato-thalamo-cortical
circuit involved in OCDmight explain why stimulation of different brain regions finally
achieves similar percentages of improvement. Stimulation of STN has been reported to
decrease OFC and mPFC metabolism as well as ACC activity [51] while stimulation of the
ALIC has similarly been associated with decreased OFC [23, 29], subgenual ACC and right
DLPFC metabolism [52]. Interestingly, while STN stimulation did not significantly modify
comorbid depressive and anxiety symptoms [33], a significant and early improvement in mood
and anxiety levels, preceding any change in OCD severity, is commonly reported in patients
receiving stimulation in striatal areas [11]. Future studies should address the local and distant
effects responsible for mutual as well as distinct mechanisms of action of DBS depending on
specific targets in order to personalize the choice of the optimal implantation area according to
the individual presentation of the illness.
Better response to DBS was associated with older age at OCD onset. Age of onset has been
postulated as an important marker for subtyping OCD. Early age of onset patients show more
severe forms of OCD, poorer prognosis for pharmacological treatment, higher familial aggre-
gation of both OCD and tic disorders, and a higher specific comorbidity pattern mainly with
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ADHD, Tourette’s syndrome and bipolar disorder [53, 54]. A few studies have directly
addressed the existence of differences in neuroimaging findings between OCD patients with
early and late onset of the disorder, with inconclusive results. Pediatric studies suggest that chil-
dren and adolescents with OCD show abnormalities of the putamen, globus pallidus and thala-
mus [55]. A recent study by Correia et al. [56] addressing the concentration of iron in the basal
ganglia suggested a neurobiological distinction between early and late onset OCD: late onset
patients, but not early onset ones, showed significantly higher iron concentrations than healthy
controls, particularly in this area, although it is not clear whether iron metabolism plays a
direct role in OCD or is just a correlation of other dysfunctions such as serotonergic neuro-
transmission. Therefore, further studies are needed to determine whether any specific struc-
tural or functional brain difference associated with early-onset OCD mediates its poorer
response to DBS.
According to the results of this meta-analysis, the presence of sexual/religious obsessions
and compulsions was associated with a significantly better response to DBS. Recent studies
have associated this OCD clinical dimension with specific brain functional connectivity pat-
terns: patients with more sexual/religious obsessions demonstrated relatively greater connectiv-
ity between the ventral caudate and the middle and anterobasal insular cortex than patients
with other symptom dimensions as well as healthy controls in a study addressing alterations of
ventral corticostriatal functional connectivity in OCD [57]. Since Figee et al. [58] recently
reported that the reduction of OCD symptoms after DBS was correlated with a fall in excessive
frontostriatal connectivity recorded at baseline, it might be hypothesized that abnormal insulo-
striatal connectivity is especially sensitive to the capacity of DBS to normalize brain connectiv-
ity. Further neuroimaging studies focusing on changes in connectivity patterns in relation to
the response to DBS of different OCD symptom dimensions are needed to confirm this
hypothesis.
The present manuscript has a number of limitations. First, the small sample sizes in the
studies included complicate the assessment of inter-study heterogeneity. The studies were het-
erogeneous in terms of anatomical targeting, electrode design and stimulation parameters.
This makes the comparison between studies difficult, and reflects the fact that DBS for OCD is
a tool that is still under development. Second, we decided to address the response to DBS in all
available patients worldwide instead of restricting our analysis to double-blind sham-con-
trolled studies, since only six of the published studies (with only 45 subjects) reported this
design in their methodology. Moreover, even in this small body of studies, the duration of
active and sham periods was not easily comparable since it lasted from minutes [20] to three
months [33], including 15 days [11], 21 days [29] or 30 days [37]. Nevertheless, in all these six
studies, active stimulation was significantly more effective than the sham condition, which had
to be shortened or cancelled in many patients due to severe clinical deterioration. There is a
need for further well-controlled randomized trials to compare active versus sham DBS. Third,
information on OCD symptom dimension, which emerged as one of the clinical predictors of
response, was not assessed using specifically designed tools in any study even though it was
available for 95 patients. The information must therefore be extracted from clinical descrip-
tions, which limits its replicability. Fourth, no meta-regression analyses could be conducted to
establish predictors of response, owing to the small number of patients included. Statistical
comparison of subgroups was used, instead, as an exploratory method to address this impor-
tant clinical issue. Finally, as in all meta-analyses, a potential publication bias and the risk of
including limited-quality trials must be considered. We tried to address these concerns by the
comprehensive and systematic review of the literature and the use of stringent inclusion
criteria.
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Although the number of severe OCD treatment-resistant patients treated with DBS is still
low, and optimal targeting and stimulation parameters are still under debate, the results of this
meta-analysis confirm that DBS constitutes an alternative to ablative surgery for this group of
extremely ill patients and presents an acceptable adverse effect profile. Further well-controlled
randomized studies in larger samples are needed to confirm and extend our findings on clinical
predictors of response, and thus to improve both patient selection and response rate.
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